ROCHESTER, NY – Vaccinex Inc., a clinical stage biotechnology company focused on the development of novel immune-based therapeutics will present information in the coming weeks surrounding VX15/2503, the company’s leading therapeutic antibody program. Two posters will be available for viewing at the 102nd annual American Association for Cancer Research (AACR) conference April 2nd -6th, 2011 in Orlando, FL. In addition, Dr. Paul Foster, Chief Medical Officer, will present at the 63rd annual American Academy of Neurology (AAN) conference in Honolulu, Hawaii on April 12th, 2011. VX15/2503 antibody targets SEMA4D, a protein that experimental evidence has suggested is involved mechanistically in angiogenesis and tumor cell proliferation and invasion. In addition, SEMA4D has been linked experimentally to inflammation and demyelination of neurons. Neutralization of SEMA4D has been shown to provide a neuroprotective effect which may ultimately benefit those who suffer from neurodegenerative disease such as multiple sclerosis. Vaccinex has initiated a phase I clinical trial of VX15/2503 antibody in cancer patients and is actively planning a second clinical trial in patients with neurodegenerative disease. Links to pertinent presentations are provided below.

(AACR) - Nonclinical Safety Assessment of VX15/2503
(AACR) - Reduction of In Vivo Tumor Growth and Angiogenesis
(AAN) - Development of Anti-SEMA4D Human Antibody for the Treatment of Multiple Sclerosis

About Vaccinex, Inc.
Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Utilizing its patented ActivMAb® antibody discovery technology, Vaccinex has developed the only library-based antibody discovery technology capable of directly expressing bivalent, fully human antibodies in mammalian cells. The company is building an impressive pipeline of therapeutic antibodies with the potential for effectively treating various autoimmune diseases and cancers. For additional information, please visit the company's website at www.vaccinex.com.